Is Bone Biologics Stock a Good Investment?
Bone Biologics Investment Advice | BBLGW |
Not Rated
Examine Bone Biologics Stock
Researching Bone Biologics' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). The company recorded a loss per share of 0.14. Bone Biologics Corp had not issued any dividends in recent years. The entity had 1:30 split on the 7th of June 2023.
To determine if Bone Biologics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Bone Biologics' research are outlined below:
Bone Biologics Corp is not yet fully synchronised with the market data | |
Bone Biologics Corp is way too risky over 90 days horizon | |
Bone Biologics Corp appears to be risky and price may revert if volatility continues | |
Bone Biologics Corp has high likelihood to experience some financial distress in the next 2 years | |
Net Loss for the year was (4.11 M) with profit before overhead, payroll, taxes, and interest of 0. | |
Bone Biologics Corp has accumulated about 4.44 K in cash with (4.12 M) of positive cash flow from operations. |
Bone Biologics' insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Bone Biologics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Bone Biologics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Bone Biologics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Understand Bone Biologics' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Bone Biologics' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
Risk Adjusted Performance | 0.0559 | |||
Market Risk Adjusted Performance | (0.42) | |||
Mean Deviation | 10.55 | |||
Coefficient Of Variation | 1944.94 | |||
Standard Deviation | 18.47 | |||
Variance | 341.02 | |||
Information Ratio | 0.0529 | |||
Jensen Alpha | 0.86 | |||
Total Risk Alpha | 1.69 | |||
Treynor Ratio | (0.43) | |||
Maximum Drawdown | 96.02 | |||
Value At Risk | (37.66) | |||
Potential Upside | 31.15 | |||
Skewness | (1.56) | |||
Kurtosis | 5.19 |
Risk Adjusted Performance | 0.0559 | |||
Market Risk Adjusted Performance | (0.42) | |||
Mean Deviation | 10.55 | |||
Coefficient Of Variation | 1944.94 | |||
Standard Deviation | 18.47 | |||
Variance | 341.02 | |||
Information Ratio | 0.0529 | |||
Jensen Alpha | 0.86 | |||
Total Risk Alpha | 1.69 | |||
Treynor Ratio | (0.43) | |||
Maximum Drawdown | 96.02 | |||
Value At Risk | (37.66) | |||
Potential Upside | 31.15 | |||
Skewness | (1.56) | |||
Kurtosis | 5.19 |
Consider Bone Biologics' intraday indicators
Bone Biologics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Bone Biologics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Bone Stock media impact
Far too much social signal, news, headlines, and media speculation about Bone Biologics that are available to investors today. That information is available publicly through Bone media outlets and privately through word of mouth or via Bone internal channels. However, regardless of the origin, that massive amount of Bone data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Bone Biologics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Bone Biologics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Bone Biologics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Bone Biologics alpha.
Bone Biologics Related Equities
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Bone Biologics stock to make a market-neutral strategy. Peer analysis of Bone Biologics could also be used in its relative valuation, which is a method of valuing Bone Biologics by comparing valuation metrics with similar companies.
Risk & Return | Correlation |
Bone Biologics Corporate Executives
Elected by the shareholders, the Bone Biologics' board of directors comprises two types of representatives: Bone Biologics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Bone. The board's role is to monitor Bone Biologics' management team and ensure that shareholders' interests are well served. Bone Biologics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Bone Biologics' outside directors are responsible for providing unbiased perspectives on the board's policies.
Shunichi Kuroda | CoFounder Board | Profile |
Additional Tools for Bone Stock Analysis
When running Bone Biologics' price analysis, check to measure Bone Biologics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bone Biologics is operating at the current time. Most of Bone Biologics' value examination focuses on studying past and present price action to predict the probability of Bone Biologics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bone Biologics' price. Additionally, you may evaluate how the addition of Bone Biologics to your portfolios can decrease your overall portfolio volatility.